1. Home
  2. TYG vs FTRE Comparison

TYG vs FTRE Comparison

Compare TYG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tortoise Energy Infrastructure Corporation

TYG

Tortoise Energy Infrastructure Corporation

HOLD

Current Price

$43.12

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$19.79

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYG
FTRE
Founded
2003
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2003
2023

Fundamental Metrics

Financial Performance
Metric
TYG
FTRE
Price
$43.12
$19.79
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$14.06
AVG Volume (30 Days)
108.8K
970.2K
Earning Date
05-04-2026
05-05-2026
Dividend Yield
11.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.09
P/E Ratio
$52.62
N/A
Revenue Growth
N/A
1.00
52 Week Low
$40.35
$8.31
52 Week High
$51.18
$21.39

Technical Indicators

Market Signals
Indicator
TYG
FTRE
Relative Strength Index (RSI) 57.37 45.16
Support Level $42.23 $17.37
Resistance Level $45.31 $18.13
Average True Range (ATR) 0.68 0.77
MACD 0.06 -0.13
Stochastic Oscillator 75.54 40.95

Price Performance

Historical Comparison
TYG
FTRE

About TYG Tortoise Energy Infrastructure Corporation

Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: